Should Humana’s (HUM) Lowered 2026 EPS Outlook and Buybacks Prompt a Rethink on Margin Recovery?

Simply Wall St.

May 04

In April 2026, Humana Inc. reported first-quarter 2026 results showing revenue of US$39,648 million, net income of US$1,186 million, diluted EPS of US$9.83, and announced completion of a US$276.13 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2632932222"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632932222\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632932222?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955","is_english":true,"pubTime":"2026-05-04 18:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632932222","market":"sg","top_or_hot":-1,"title":"Should Humana’s (HUM) Lowered 2026 EPS Outlook and Buybacks Prompt a Rethink on Margin Recovery?","media":"Simply Wall St.","content":"<div>\n<p>In April 2026, Humana Inc. reported first-quarter 2026 results showing revenue of US$39,648 million, net income of US$1,186 million, diluted EPS of US$9.83, and announced completion of a US$276.13 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/should-humanas-hum-lowered-2026-eps-outlook-and-buybacks-pro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Humana’s (HUM) Lowered 2026 EPS Outlook and Buybacks Prompt a Rethink on Margin Recovery?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Humana’s (HUM) Lowered 2026 EPS Outlook and Buybacks Prompt a Rethink on Margin Recovery?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-04 18:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/should-humanas-hum-lowered-2026-eps-outlook-and-buybacks-pro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In April 2026, Humana Inc. reported first-quarter 2026 results showing revenue of US$39,648 million, net income of US$1,186 million, diluted EPS of US$9.83, and announced completion of a US$276.13 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/should-humanas-hum-lowered-2026-eps-outlook-and-buybacks-pro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HUM.AU","symbol_name":"HUMM GROUP LTD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/should-humanas-hum-lowered-2026-eps-outlook-and-buybacks-pro","article_id":"2632932222","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/should-humanas-hum-lowered-2026-eps-outlook-and-buybacks-pro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632932222","pubTimestamp":1777889614,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In April 2026, Humana Inc. reported first-quarter 2026 results showing revenue of US$39,648 million, net income of US$1,186 million, diluted EPS of US$9.83, and announced completion of a US$276.13 million share repurchase program covering 1% of its shares.\nOn the same day, Humana lowered its full-year 2026 GAAP diluted EPS guidance to at least US$8.36, signaling that profitability expectations have softened even as top-line growth continues.\nNext, we’ll examine how Humana’s reduced 2026...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HUM.AU":"HUMM GROUP LTD"},"translate_title":"Humana(HUM)下调2026年每股收益预期和回购是否会促使人们重新考虑利润率恢复？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUM.AU":1.5},"content_text":"In April 2026, Humana Inc. reported first-quarter 2026 results showing revenue of US$39,648 million, net income of US$1,186 million, diluted EPS of US$9.83, and announced completion of a US$276.13 million share repurchase program covering 1% of its shares. On the same day, Humana lowered its full-year 2026 GAAP diluted EPS guidance to at least US$8.36, signaling that profitability expectations have softened even as top-line growth continues. Next, we’ll examine how Humana’s reduced 2026 earnings guidance reshapes its existing investment narrative built around Medicare Advantage margin recovery. Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementHumana Investment Narrative RecapTo own Humana today, you need to believe in its core Medicare Advantage and CenterWell platform while accepting that earnings may be bumpy. The Q1 2026 beat on revenue but cut to full year GAAP EPS guidance to at least US$8.36 keeps the near term focus squarely on margin recovery, while the biggest risk remains how reimbursement, coding changes, and Stars outcomes feed through to medical costs and profitability. The guidance change appears material for near term expectations. The most relevant recent move alongside earnings was Humana’s completion of its US$276.13 million buyback, retiring about 1% of shares. In the context of lower EPS guidance and past one off losses, this looks like a relatively modest use of capital that now sits alongside a steady US$0.885 quarterly dividend. For investors tracking catalysts, it underscores that management is keeping capital returns measured while it works through Medicare Advantage margin and regulatory uncertainties. Yet alongside the margin reset, investors should also be aware of how MACRA’s V28 coding changes could affect high acuity members and... Read the full narrative on Humana (it's free!)Humana's narrative projects $184.2 billion revenue and $3.1 billion earnings by 2029.Uncover how Humana's forecasts yield a $210.46 fair value, a 10% downside to its current price.Exploring Other PerspectivesHUM 1-Year Stock Price Chart Some of the most pessimistic analysts were only assuming revenue near US$129.7 billion and earnings of about US$2.4 billion by 2028, so this latest guidance cut may push their already cautious Medicare Advantage margin concerns even further and is a reminder that your view on Humana can differ sharply from theirs.Explore 9 other fair value estimates on Humana - why the stock might be worth over 4x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Humana research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.No Opportunity In Humana?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Humana might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}